Macrolide-resistant Mycoplasma pneumoniae, United States

Creator(s)

Xiaotian Zheng, Northwestern University Feinberg School of Medicine
Stella Lee, Northwestern University Feinberg School of Medicine
Rangaraj Selvarangan, Children's Mercy HospitalFollow
Xuan Qin, Seattle Children's Hospital
Yi Wei Tang, Weill Cornell Medicine
Jeffrey Stiles, Weill Cornell Medicine
Tao Hong, Hackensack University Medical Center
Kathleen Todd, Northwestern University Feinberg School of Medicine
Amy E. Ratliff, The University of Alabama at Birmingham
Donna M. Crabb, The University of Alabama at Birmingham
Li Xiao, The University of Alabama at Birmingham
T. Prescott Atkinson, The University of Alabama at Birmingham
Ken B. Waites, The University of Alabama at Birmingham

Document Type

Article

Publication Date

7-23-2015

Identifier

DOI: 10.3201/eid2108.150273; PMCID: PMC4517703

Abstract

© 2015, Centers for Disease Control and Prevention (CDC). All rights reserved.

Macrolide-resistant Mycoplasma pneumoniae (MRMP) is highly prevalent in Asia and is now being reported from Europe. Few data on MRMP are available in the United States. Using genotypic and phenotypic methods, we detected high-level MRMP in 13.2% of 91 M. pneumoniae–positive specimens from 6 US locations.

Journal Title

Emerging Infectious Diseases

Volume

21

Issue

8

First Page

1470

Last Page

1472

Keywords

MIC; Mycoplasma pneumoniae; United States; antimicrobial resistance; bacteria; children; macrolide

Recommended Citation

Zheng X, Lee S, Selvarangan R, et al. Macrolide-Resistant Mycoplasma pneumoniae, United States. Emerg Infect Dis. 2015;21(8):1470-1472. doi:10.3201/eid2108.150273